Endocrinology

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Hypoglycemia unawareness increased over time with use of sulfonylureas but decreased with use of insulin over the same period, a new study found.

Based on guidance from the American Society of Preventive Cardiology, this topline summarizes risk factors and interventions to reduce the risk of major adverse CV events.

The significant rise in new GLP-1 RA prescriptions between 2011 and 2023 saw a doubling in the proportion written for obesity and a decline in those for T2D.

Adherence to Mediterranean diet-based interventions was associated with reductions in BP, triglycerides, total cholesterol, and LDL-C, as well as increases in HDL-C among children and adolescents.

Results from secondary analysis suggest future work is needed to extend the prevention intervention to address additional chronic conditions and substance use.

Your daily dose of the clinical news you may have missed.

The antigen-specific immunotherapy preserves endogenous insulin production via intralymphatic injection of recombinant GAD65 protein, according to Diamyd Medical.

Adiposity before age 60 to 64 years, beginning as early as age 20 years, was associated with adverse cardiac structure and function not explained by current BMI.

The oral GLP-1 RA was associated with weight loss of 7.3% in just 4 weeks and is designed with unique properties that will enhance multiple outcomes, Roche said.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

In the mouse model of type 1 diabetes, a combined harmine/exendin-4 therapy resulted in an up to 7-fold increase in β cell numbers over 3 months, reported investigators.

Findings from the large meta-analysis provide strong support for use of both classes to reduce CV and renal disease in adults with type 2 diabetes.

Long-term risk of death decreased by 26% and risk for vascular complications decreased by 40% in persons who remained diabetes-free for 4 years, according to new data.

The agency is concerned about manufacturing processes involved in production and about the proposed indication for adults with type 1 diabetes.

Your daily dose of the clinical news you may have missed.

Tirzepatide-treated participants were 3 times more likely than those treated with semaglutide to reach weight loss of 15% or greater, the head-to-head study found.

GLP-1RAs were associated with a significantly reduced risk of obesity-associated cancers including gallbladder cancer, pancreatic cancer, and meningioma.

The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.

The international statement targets primary care clinicians and endocrinologists with detailed guidance on monitoring disease progression and providing education.

The risk for developing CVD and T2D was highest among individuals who frequently experienced the behavior in the workplace, according to new study.

Investigational treatments for congenital adrenal hyperplasia are focused on new ways to manage symptoms without the need for supraphysiologic doses of glucocorticoids.

ADA 2024. Adults started on the Omnipod 5 AID system had an A1c reduction from 8.2% at baseline to 7.4% at 13 weeks, researchers report.

ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.

Your daily dose of the clinical news you may have missed.

This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.